Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seoul-based IVI Partners With Indian Shantha Biotechnics For Low-Cost Cholera Vaccine Licensed in India

This article was originally published in PharmAsia News

Executive Summary

SEOUL - A new oral cholera vaccine developed by Seoul-based International Vaccine Institute has been licensed to India's Shantha Biotechnics, paving the way for worldwide use of a low-cost cholera vaccine in developing countries, where most cholera cases occur, the IVI said
Advertisement

Related Content

Inviragen Finds New Life For Shelved Japanese Encephalitis Vaccine At State-Owned VABIOTECH
India’s Shantha Biotech Draws Interest From MNCs And Universities Alike
India’s Shantha Biotech Draws Interest From MNCs And Universities Alike
Advertisement
UsernamePublicRestriction

Register

SC071430

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel